



Successful Treatment of Insomnia with Melatonin in a Patient with Malignant Glioma after Radiotherapy-Involving the Pineal Gland

Reim A¹, Strobl D², Saletu-Zyhlarz G³, Preusser M^{2,5}, Schmook MT⁴, Dieckmann K^{1,5}, Zielinski CC² and Marosi C^{2,5*}

¹Department of Radiotherapy and Radiobiology, Medical University of Vienna, Austria

²Department of Medicine I, Medical University of Vienna, Austria

³Department of Psychiatry, Medical University of Vienna, Austria

⁴Department of Radiology, Medical University of Vienna, Austria

⁵Comprehensive Cancer Center – Central Nervous System Tumours Unit, Medical University of Vienna, Austria

Abstract

A 29 year old female patient suffering from a biopsy proven anaplastic astrocytoma in the right basal ganglia was treated by conformal radiation therapy with 2 Gy/fraction up to 60 Gy. Near the end of radiotherapy she complained about insomnia. Her previous sleep pattern has been inconspicuous, but now – despite high dose of benzodiazepines provided by her family physician - she was unable to fall asleep until 2 am and to stay asleep for longer than two hours. Following the hypothesis that melatonin secretion had been impaired by radiotherapy, the patient was given 3 mg of melatonin orally at bedtime with immediate and ongoing restauration of sleep pattern.

Keywords: Insomnia; Melatonin; Hypothalamic

Introduction

A recent survey reported on conspicuous prevalence and severity of sleep disorders in patients with cancer. Insomnia is defined as difficulty falling asleep, difficulty staying asleep – with wake episodes of more than half an hour – unintended early awakening and nonrestorative sleep. This symptom complex qualifies as insomnia when it occurs at least three times a week, results in distress and impairs day time functioning. In cancer patients, especially in patients complaining about fatigue and insomnia is under diagnosed and undertreated [1-7].

Insomnia is also very common in patients with malignant gliomas, although not frequently as striking as in the patient reported here [8].

Case Presentation

A female patient aged 29 years was diagnosed with anaplastic glioma of 3 cm diameter in the basal ganglia of the right hemisphere (Figure 1). The tumor was biopsied. Subsequently the patient

OPEN ACCESS

*Correspondence:

Christine Marosi, Department of Medicine I, Division of Oncology, Medical University of Vienna, Comprehensive Cancer Center – Central Nervous System Tumours Unit (CCC-CNS), Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria, Tel: + 43 (0)1 40160-11402; Fax: +43 (0)1 40160-911400; E-mail: christine.marosi@meduniwien.ac.at

Received Date: 16 Jun 2016

Accepted Date: 24 Aug 2016

Published Date: 16 Sep 2016

Citation:

Reim A, Strobl D, Saletu-Zyhlarz G, Preusser M, Schmook MT, Dieckmann K, et al. Successful Treatment of Insomnia with Melatonin in a Patient with Malignant Glioma after Radiotherapy-Involving the Pineal Gland. *Remed Open Access*. 2016; 1: 1017.

Copyright © 2016 Marosi C. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.




Figure 1: Initial radiologic findings. Brain MRI demonstrates 3.2 × 2.8 cm lesion without contrast enhancement in the T1 weighted image (A) and with edema on flair image (B) before biopsy and radiation therapy. MRI: magnetic resonance imaging.




Figure 2: Irradiation plan showing the isodoses (red-violet-blue), brainstem (green), and pineal gland (pink).

Name	Min [Gy]	Max [Gy]	Median [Gy]	Average [Gy]	Std. Dev [Gy]
Brainstream	1.86	59.06	39.00	38.17	18.79
Chiasm	43.75	49.65	48.69	47.36	14.96
CTV	54.16	62.82	59.78	59.61	1.86
Eye, Left	2.11	3.63	2.67	2.69	0.37
Eye, Right	2.67	4.71	3.39	3.42	0.54
Lens, Left	-	-	-	-	-
Lens, Right	-	-	-	-	-
Optic Nerve	3.50	5.51	4.21	4.45	1.77
Optic Nerve	4.44	10.16	6.11	6.41	5.12
PTV 5 mm	48.23	62.82	59.51	59.26	2.42
Tumor	56.93	61.97	59.71	59.65	1.02
Body	0.00	62.82	4.71	13.32	16.56
Epiphyse	33.99	54.03	42.78	42.89	7.85

Table 1: Minimal, maximal, median and average doses of the risk organs and CTV (clinical target volume), PTV (planning target volume).

underwent conformal radiotherapy with 2 Gy single doses up to 60 Gy. Because of headaches three weeks after the start of radiation, she was treated with dexamethasone up to 12 mg daily.

Two weeks later, she reported that her headache was gone, but that she was continuously active day and night, felt restlessly “driven from outside”. Going to bed around 10 pm ordinarily she was now unable to fall asleep before 2 am and woke up 1.5 to 2 hours later. Because of sleep deprivation, her family physician prescribed nitrazepam 5 mg taken at bedtime. Despite an increase of the nitrazepam (dose of up to 4 tablets) her sleep lasted no longer than two hours.

A capsule with 3 mg of melatonin taken at 10 pm allowed her to fall asleep again and to stay asleep for five to six hours from the first day of administration of melatonin, even without benzodiazepine medication on subsequent days. She had regenerative sleep again and felt active at day time.

Discussion

The hormone melatonin (*N*-acetyl-5-methoxytryptamine) is secreted in the pineal gland during darkness or when the absorption of blue light (484 nm) is blocked. Melatonin is an important factor of the sleep-wake cycle, mainly regulated by the suprachiasmatic nuclei of the hypothalamus [9,10]. In the US, melatonin is widely used as

over the counter medicine against sleep disorders, jet lag and various other conditions as it is a powerful antioxidant, whereas in Europe, its medical use focuses on insomnia in persons above the age of 55 years. However, with rare exceptions, melatonin is well tolerated in doses below 5 mg [11-15] and potential anti-tumoral effectiveness of melatonin has been discussed [16].

The patient mentioned in this report showed multiple causes for disturbed sleep, starting from reactive depression over an incurable tumor disease, increased stress about this illness and its sequelae for her personal situation and the family, disruption of sleeping pattern due to the anti-edematous medication with dexamethasone [17-22] and a possible hypomanic state due to this same medication [23].

In the patient of this report, the radiation field covered the epiphysis as well as both hypothalamic suprachiasmatic nuclei, where the circadian rhythms of waking and sleep are regulated (Figure 2 and Table 1). Trying melatonin therapy was obvious – and successful. Thus, in patients with radiation fields covering the hypothalamus or the epiphysis with insomnia, the administration of melatonin may offer restoration of satisfactory sleep patterns.

References

1. Savard J, Ivers H, Villa J, Caplette-Gingras A, Morin CM. Natural course

- of insomnia comorbid with cancer: an 18-month longitudinal study. *J Clin Oncol*. 2011; 29: 3580-6.
2. Enderlin CA, Coleman EA, Cole C, Richards KC, Kennedy RL, Goodwin JA, et al. Subjective sleep quality, objective sleep characteristics, insomnia symptom severity, and daytime sleepiness in women aged 50 and older with nonmetastatic breast cancer. *Oncol Nurs Forum*. 2011; 38: E314-25.
 3. Dirksen SR, Epstein DR, Hoyt MA. Insomnia, depression and distress among outpatients with prostate cancer. *Appl Nurs Res*. 2009; 22: 154-158.
 4. Donovan KA, Jacobsen PB. Fatigue, depression and insomnia: evidence for a symptom cluster in cancer. *Semin Oncol Nurs*. 2007; 23: 127-35.
 5. O'Donnell JF. Insomnia in cancer patients. *Clin Cornerstone*. 2004; 6: S6-S14.
 6. Silberfarb PM, Hauri PJ, Oxman TE, Lash S. Insomnia in cancer patients. *Soc Sci Med*. 1985; 20: 849-850.
 7. Beszterczey A, Lipowski ZJ. Insomnia in cancer patients. *Can Med Assoc J*. 1977; 116: 355.
 8. Yuile P, Dent O, Cook R, Biggs M, Little N. Survival of glioblastoma patients related to presenting symptoms, brain site and treatment variables. *J Clin Neurosci*. 2006; 13: 747-51.
 9. Dubocovich ML. Melatonin receptors: Role on sleep and circadian rhythm regulation. *Sleep Med*. 2007; 8: 34-42.
 10. Dijk DJ, Cajochen C. Melatonin and the circadian regulation of sleep initiation, consolidation, structure and the sleep EEG. *J Biol Rhythms*. 1997; 12: 627-635.
 11. Lemoine P, Wade AG, Katz A, Nir T, Zisapel N. Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials. *Integr Blood Press Control*. 2012; 5: 9-17.
 12. Yousaf, F, Seet E, Venkatraghavan L, Abrishami A, Chung F. Efficacy and safety of melatonin as an anxiolytic and analgesic in the perioperative period: a qualitative systematic review of randomized trials. *Anesthesiology*. 2010; 113: 968-76.
 13. Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. *BMJ*. 2006; 332: 385-93.
 14. Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. *J Gen Intern Med*. 2005; 20: 1151-1158.
 15. Arendt J. Safety of melatonin in long-term use (?). *J Biol Rhythms*. 1997; 12: 673-681.
 16. Wion D, Berger F, Wion-Barbot N. Glioma, melatonin, and radiotherapy. *Cancer research*. 2006; 66: 6457.
 17. Daniel LC, Li Y, Kloss JD, Reilly AF, Barakat LP. The impact of dexamethasone and prednisone on sleep in children with acute lymphoblastic leukemia. *Support Care Cancer*. 2016; 24: 3897-906.
 18. Rosen G, Harris Ak, Liu M, Dreyfus J, Krueger J, Messinger YH. The effects of dexamethasone on sleep in young children with acute lymphoblastic leukemia. *Sleep Med*. 2015; 16: 503-509.
 19. Luik AI, Direk N, Zuurbier LA, Hofman A, Van Someren EJ, Tiemeier H. Sleep and 24-h activity rhythms in relation to cortisol change after a very low-dose of dexamethasone. *Psychoneuroendocrinology*. 2015; 53: 207-16.
 20. Hori H, Teraishi T, Sasayama D, Ozeki Y, Matsuo J, Kawamoto Y, et al. Poor sleep is associated with exaggerated cortisol response to the combined dexamethasone/CRH test in a non-clinical population. *J Psychiatr Res*. 2011; 45: 1257-63.
 21. Vallance K, Liu W, Mandrell BN, Panetta JC, Gattuso JS, Hockenberry M, et al. Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL. *Eur J Cancer*. 2010; 46: 1848-1855.
 22. Moser NJ, Phillips BA, Guthrie G, Barnett G. Effects of dexamethasone on sleep. *Pharmacol Toxicol*. 1996; 79: 100-102.
 23. Watanabe TK, Sylvester CE, Manaligod JM. Mania or panic associated with dexamethasone chemotherapy in adolescents. *J Adolesc Health*. 1994; 15: 345-347.